Skip Navigation

  1. About Us
    1. Overview
    2. History
    3. Recognition
    4. Offices
  2. Our Practice
    1. Practice Areas
      1. Patents, Utility Models, and Industrial Designs
      2. Trademarks
      3. Copyrights
      4. Corporate, Commercial and Business Law
      5. IP Litigation, Alternative Dispute Resolution
      6. Regulatory Law
      7. Licensing, Tech Transfer & Franchising
      8. Anti-Piracy, Anti-Counterfeiting & Enforcement
    2. Industry Groups
      1. Media, Sports & Entertainment Law Group
      2. Life Science & Pharmaceutical Law Group
  3. Our People
    1. Partners
      1. Sergio L. Olivares, Sr. † (1931-2010)
      2. Sergio L. Olivares, Jr.
      3. Luis C. Schmidt
      4. Cesar Ramos, Jr.
      5. Antonio Belaunzaran
      6. Gustavo A. Alcocer
      7. Jose Ignacio De Santiago
      8. Alejandro Luna
      9. Alonso Camargo
      10. Daniel Sanchez
    2. Associates (A - M)
      1. Osvaldo Amaral
      2. Armando Arenas
      3. Sofía Arroyo
      4. Guillermo Ballesteros
      5. Varinia Calleros
      6. Abraham Diaz
      7. Georgina Flores
      8. Pedro Herrera
      9. Carlos Maya
    3. Associates (N - Z)
      1. Mauricio Narváez
      2. Víctor Ramírez
      3. Sergio Rangel
      4. Maria del Carmen Sada
      5. Juan Luis Serrano
      6. Guillermo Treviño
      7. Carlos Woodworth
    4. All Attorneys / Engineers
    5. Firm Administration
  4. Knowledge & Resources
    1. Articles
      1. Trademark Law Articles
        1. Use requirements
        2. Approach to composite marks changed, again
        3. Life Sciences Handbook 2011 - Country Q&A
        4. Mexico should accept secondary meaning
        5. Getting the Deal Through - Trademarks 2011
        6. Pharmaceutical Trademarks 2010/2011 - A Global Guide
        7. No legal basis for banning names derived from INNs
        8. How Latin America tackles cutting-edge IP issues
        9. Specialised IP court corrects IMPI
        10. Protecting trade dress
        11. 43 more items...
      2. Patent Law Articles
        1. Mexico issues regulations to approve biologic drugs
        2. Latin America Roundtable
        3. New regulations pending
        4. The International Comparative Guide
        5. Marketing authorization for pharmaceutical
        6. Approval of follow-on biologics in Mexico
        7. Mexican Linkage Gazette April 2011
        8. Patent Prosecution Highway in Mexico
        9. Life Sciences Handbook 2011 - Country Q&A
        10. Data Package Exclusivity (DPE)
        11. 35 more items...
      3. Copyright Law Articles
        1. Advertising in social media networks
        2. Technology challenges digital rights
        3. Exceptions to copyright protection and the permitted uses of copyright works in the hi-tech and digital sectors
        4. Derechos sobre producción audiovisual
        5. How Latin America tackles cutting-edge IP issues
        6. Copyright Litigation 2010
        7. Legislation and enforcement - Copyrights 2010
        8. Valuing folklore
        9. Protecting novel ideas
        10. Mexico's fair use balancing act
        11. 100 more items...
      4. Corporate Law Articles
        1. Mexico issues Personal Data Protection Rules
        2. How data affects innovation
        3. A practical cross-border
        4. New registry for security interests
        5. The International Comparative Legal Guide to: Merger Control 2011
        6. The International Comparative Legal Guide to: Merger Control 2010
        7. Due diligence issues to consider in M&A
        8. Income expectations in licensing
        9. The reasons for valuation
        10. Amendments proposed to franchise regulation
      5. IP Litigation, ADR Articles
        1. Scope of new specialised courts widened
        2. Reform of preliminary injunctions
        3. Mexican Patent Office excludes Formulation Patents from Linkage Gazette
        4. Mexico gets ready to approve biocomparable drugs
        5. Mexico's hotel for the stars highlights power in the name
        6. Supreme Court upholds the worth of formulation patents
        7. Getting the Deal Through - Patents 2010
        8. Getting the Deal Through Trademarks 2010
        9. Trademark enforcement
        10. Venues for appealing IMPI decisions
        11. 15 more items...
      6. Regulatory Law Articles
        1. Amendments to the Federal Law for Consumer Protection
        2. Mexico issues Personal Data Protection Rules
        3. New Regulations Pending
        4. Marketing authorization for pharmaceutical products to foreign applicants
        5. Data Package Exclusivity (DPE)
        6. Supreme Court upholds the worth of formulation patents
        7. Pharmaceutical trademarks
        8. Framework for biotherapeutic products established
        9. Pharmaceutical Advertising 2009
        10. New Regulations for pharma industry
        11. 3 more items...
      7. Licensing, Tech Transfer Articles
        1. Creating a secure franchise system
      8. Anti-Piracy, Anti-Counterfeiting Articles
        1. New register against counterfeits
        2. Beat the counterfeiters in Mexico
        3. Battling counterfeits through Customs
        4. Getting the Deal Through Trademarks 2010
        5. Enforcing plant variety rights in Mexico
        6. Pharmaceutical Trademarks 2009
        7. Internet Issues
        8. Anti-counterfeiting 2009
        9. Vegetal variety rights enforced
        10. New Customs rules lead to seizures
        11. 3 more items...
      9. Media, Sports & Entertainment Focused Articles
        1. Whither Rental Rights?
        2. Improved protection for personalities
      10. Life Sciences Focused Articles
        1. Latin America Roundtable
        2. New regulations pending
        3. The International Comparative
        4. Approval of follow-on biologics in Mexico
        5. Global Pharmaceutical Linkage Regulations:
        6. Life Sciences Handbook 2011 - Country Q&A
        7. Supreme Court upholds the worth of formulation patents
        8. Repercussions expected on medicine advertising campaign in Mexico
        9. Framework for biotherapeutic products established
        10. Pharmaceutical Trademarks 2009
        11. 1 more item...
    2. Webinar Archive
      1. Webinar - Changes to Mexican Patent and Healthcare Laws for Life Sciences
      2. Webinar - Digital Rights Issues in Copyright Law
      3. Webinar - Data Package Exclusivity Rights in Latin America
    3. Recognition
    4. News
      1. Presumed Guilty - How can a law firm help win an Emmy?
      2. New rules came in force to speed timeframes in administrative appeal proceedings
      3. Recent reforms to the Mexican Industrial Property Law dealing with trademark priority rights
      4. Olivares & Cia. ranking
      5. Data Package Exclusivity (DPE)
      6. Mr. Sergio Olivares Sr's Passing
      7. Pharma Linkage Regulations Supreme Court Decision
      8. Managing IP magazine has recognized Olivares & Cia. as the leading firm for patent work in Mexico
      9. Mexican Congress amends the Patent Law
      10. Implementation of the Federal Law for the Protection of Personal Data in Possession of Private Entities
  5. Events
  6. Offices
  7. Contact Us
  8. Quick guide to Mexico’s regulatory system
    1. Patent regulatory overview
    2. Trademark regulatory overview
    3. Copyright regulatory overview
    4. Corporate & Commercial Regulatory overview

Home » Knowledge & Resources » Articles » Trademark Law Articles » Specialised IP court corrects IMPI

Specialised IP court corrects IMPI

By Carlos Reyes
Managing Intellectual Property, International Briefings, May 2010
The Mexican Trademark Office (IMPI) usually applies strict criteria concerning trade mark likelihood of confusion and distinctiveness. In order to determine marks’ confusing similarity, examiners base their exam on an “analysis of the similarities”, determining this from the existence of a common element and disregarding the marks’ overall impression.
Additionally, examiners almost never make any analysis of the different elements’ distinctiveness, so whether there are strong or weak elements is considered mostly irrelevant, and design elements have been consistently disregarded.
As an example of this, examiners have stated that: “as trademarks are signs derived of thehuman creativity, which purpose is to distinguish product or services from other of the same kind in the market, there is no reason to allow between them the existence of the slightest resemblance”. Concerning distinctiveness, IMPI has also denied distinctive signs on the basis that any suggestive informative content in relation or not with the product/services is often held as descriptive character.
This is why it is important to mention the criteria the IP Specialized Court of our Federal Court for Tax and Administrative Affairs (FCTAA) has been developing since its creation on 2009, by which this Court has been correcting IMPI. The Court has stated that confusing similarity and descriptiveness should always be based on the marks’overall impression, also defining the relevant consumer as a purchaser with average intelligence and “ordinary” caution. Additionally, the Court has repeatedly stated that when studying a mark it is important to determine its weak and dominant elements.
The Court has also separated suggestive from descriptive marks by analysing the cognitive effort their message requires from consumers, and has also stated that the meaning of descriptive foreign terms must be accessible to the consumer.